Abstract
Background
Neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer offers theoretical advantages over the standard approach of surgery followed by adjuvant CRT. We hypothesized that histological responses to CRT would be significant prognostic factors in patients undergoing neoadjuvant CRT followed by resection.
Methods
Since 1994, 193 patients with biopsy-proven pancreatic adenocarcinoma have completed neoadjuvant CRT, and 70 patients have undergone resection. Specimens were retrospectively examined by an individual pathologist for histological responses (tumor necrosis, tumor fibrosis, and residual tumor load) and immunohistochemical staining for p53 and epidermal growth factor receptor. Factors influencing overall survival were analyzed with the Kaplan-Meier (univariate) and Cox proportional hazards (multivariate) methods.
Results
The estimated overall survival (median ± SE) in the entire group of patients undergoing resection was 23 ± 4.2 months, with an estimated 3-year survival of 37% ± 6.6% and a median follow-up of 28 months. Complete histological responses occurred in 6% of patients. Overexpression of p53 was more common in patients with large residual tumor loads. Tumor necrosis was an independent negative prognostic factor, as were positive lymph nodes, a large residual tumor load, and poor tumor differentiation.
Conclusions
Histological response to neoadjuvant CRT—as measured by residual tumor load—may be useful as a surrogate marker for treatment efficacy. Characterization of the tumor cells that survive neoadjuvant CRT may help us to identify new or more appropriate targets for systemic therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
TA Sohn CJ Yeo JL Cameron et al. (2000) ArticleTitleResected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 567–79 Occurrence Handle10.1016/S1091-255X(00)80105-5 Occurrence Handle1:STN:280:DC%2BD3Mzlt1yqtA%3D%3D Occurrence Handle11307091
MH Kalser SS Ellenberg (1985) ArticleTitlePancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 899–903 Occurrence Handle1:STN:280:BiqB2M7gsVc%3D Occurrence Handle4015380
JH Klinkenbijl J Jeekel T Sahmoud et al. (1999) ArticleTitleAdjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 776–82 Occurrence Handle10.1097/00000658-199912000-00006 Occurrence Handle1:STN:280:DC%2BD3c%2FotFKkug%3D%3D Occurrence Handle10615932
JP Neoptolemos JA Dunn DD Stocken et al. (2001) ArticleTitleAdjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial Lancet 358 1576–85 Occurrence Handle10.1016/S0140-6736(01)06651-X Occurrence Handle1:CAS:528:DC%2BD3MXosFKmtro%3D Occurrence Handle11716884
F Spitz J Abruzzese J Lee et al. (1997) ArticleTitlePreoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas J Clin Oncol 15 928–37 Occurrence Handle1:STN:280:ByiB3MzosVU%3D Occurrence Handle9060530
SG Swisher JA Ajani R Komaki et al. (2003) ArticleTitleLong-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer Int J Radiat Oncol Biol Phys 57 120–7
AM Lowy PF Mansfield SD Leach R Pazdur P Dumas JA Ajani (1999) ArticleTitleResponse to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer Ann Surg 229 303–8
NA Janjan J Abbruzzese R Pazdur et al. (1999) ArticleTitlePrognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer Radiother Oncol 51 153–60 Occurrence Handle10.1016/S0167-8140(99)00054-7 Occurrence Handle1:STN:280:DyaK1Mzmt1Wrtw%3D%3D Occurrence Handle10435807
MW Onaitis RB Noone R Fields et al. (2001) ArticleTitleComplete response to neoadjuvant chemoradiation for rectal cancer does not influence survival Ann Surg Oncol 8 801–6
JP Hoffman S Lipsitz T Pisansky JL Weese L Solin AB Benson SuffixIII (1998) ArticleTitlePhase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study J Clin Oncol 16 317–23 Occurrence Handle1:CAS:528:DyaK1cXmsFeqsg%3D%3D Occurrence Handle9440759
R White H Hurwitz C Lee et al. (2001) ArticleTitleNeoadjuvant chemoradiation for localized adenocarcinoma of the pancreas Ann Surg Oncol 8 758–65
CA Iacobuzio-Donahue B Ryu RH Hruban SE Kern (2002) ArticleTitleExploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion Am J Pathol 160 91–9
TW Yen NP Aardal MP Bronner et al. (2002) ArticleTitleMyofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas Surgery 131 129–34
Y Shimosato S Oboshi K Baba (1971) ArticleTitleHistological evaluation of effects of radiotherapy and chemotherapy for carcinomas Jpn J Clin Oncol 1 19–35
DB Evans TA Rich DR Byrd et al. (1992) ArticleTitlePreoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas Arch Surg 127 1335–9 Occurrence Handle1:STN:280:ByyD2svjvVE%3D Occurrence Handle1359851
TM Breslin KR Hess DB Harbison et al. (2001) ArticleTitleNeoadjuvant chemoradiation for adenocarcinoma of the pancreas: treatment variables and survival duration Ann Surg Oncol 8 123–32
RR White EK Paulson K Freed et al. (2001) ArticleTitleStaging of pancreatic cancer before and after neoadjuvant chemoradiation J Gastrointest Surg 5 626–33
HA Burris SuffixIII MJ Moore J Andersen et al. (1997) ArticleTitleImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403–13 Occurrence Handle1:CAS:528:DyaK2sXlsFKksLY%3D Occurrence Handle9196156
Y Sato Y Nio MM Song et al. (1997) ArticleTitlep53 protein expression as prognostic factor in human pancreatic cancer Anticancer Res 17 2779–88
M Mohiuddin D Chendil S Dey RA Alcock W Regine MM Ahmed (2002) ArticleTitleInfluence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells Anticancer Res 22 825–30
M Dong Y Nio K Yamasawa T Toga L Yue T Harada (2003) ArticleTitlep53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer J Surg Oncol 82 111–20
K Uegaki Y Nio Y Inoue et al. (1997) ArticleTitleClinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer Anticancer Res 17 3841–7
HQ Xiong JL Abbruzzese (2002) ArticleTitleEpidermal growth factor receptor-targeted therapy for pancreatic cancer Semin Oncol 29 IssueID5 (Suppl) 14 31–7 Occurrence Handle10.1053/sonc.2002.35645 Occurrence Handle1:CAS:528:DC%2BD38XoslWiur8%3D
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
White, R.R., Xie, H.B., Gottfried, M.R. et al. Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer. Ann Surg Oncol 12, 214–221 (2005). https://doi.org/10.1245/ASO.2005.03.105
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2005.03.105